These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18589796)

  • 1. [The expression of receptor activator nuclear factor-kappaB ligand and osteoprotegerin in cholesteatoma].
    Ma Y; Ye S
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Apr; 22(7):293-5. PubMed ID: 18589796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of nuclear factor-kappa B ligand and correlation factor in the tissue of otitis media with cholesteatoma].
    Xia M; Ding S; Zhang H; Liu F; Yin H; Xu A
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Apr; 21(7):315-7. PubMed ID: 17580719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPG, RANK and RANK ligand expression in thyroid lesions.
    Heymann MF; Riet A; Le Goff B; Battaglia S; Paineau J; Heymann D
    Regul Pept; 2008 Jun; 148(1-3):46-53. PubMed ID: 18367263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
    Wang J; Wang K; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical localization of RANK, RANKL and OPG in healthy and arthritic canine elbow joints.
    Spahni AI; Schawalder P; Rothen B; Bosshardt DD; Lang N; Stoffel MH
    Vet Surg; 2009 Aug; 38(6):780-6. PubMed ID: 19674422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of RANKL and OPG in middle ear cholesteatoma tissue.
    Jeong JH; Park CW; Tae K; Lee SH; Shin DH; Kim KR; Park YW
    Laryngoscope; 2006 Jul; 116(7):1180-4. PubMed ID: 16826057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoclasts are not activated in middle ear cholesteatoma.
    Koizumi H; Suzuki H; Ikezaki S; Ohbuchi T; Hashida K; Sakai A
    J Bone Miner Metab; 2016 Mar; 34(2):193-200. PubMed ID: 25796629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of calcitriol on the expression of vitamin D receptor, RANKL and osteoprotegerin in human periodontal ligament cells].
    Tang XL; Meng HX; Zhang L
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2008 Dec; 43(12):732-6. PubMed ID: 19134349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANK signalling in bone lesions with osteoclast-like giant cells.
    Won KY; Kalil RK; Kim YW; Park YK
    Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the rank of RANKL in spondylarthritis?
    Loddenkemper K; Burmester GR
    Arthritis Rheum; 2008 Mar; 58(3):641-4. PubMed ID: 18311809
    [No Abstract]   [Full Text] [Related]  

  • 13. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone metastasis: can osteoclasts be excluded?
    Martin TJ; Mundy GR
    Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL signaling in bone physiology and cancer.
    Dougall WC
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
    Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
    Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media.
    Kuczkowski J; Sakowicz-Burkiewicz M; Iżycka-Świeszewska E
    Am J Otolaryngol; 2010; 31(6):404-9. PubMed ID: 20015790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.